Combined Targeting of PARG and Wee1 Causes Decreased Cell Survival and DNA Damage in an S-Phase–Dependent Manner
Lebaron C. Agostini(Sidney Kimmel Cancer Center), Jonathan R. Brody(Oregon Health & Science University)
Cited by 8
Related Papers
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
|The Lancet Oncology|2020|541
A Novel 3DNA® Nanocarrier effectively delivers payloads to pancreatic tumors
|Translational Oncology|2023|7